Evaluation of Electrodermal Activity in Diabetic Rats Treated with Vildagliptin and Metformin

ABSTRACT

Background: Electrodermal activity (EDA) is a measurement of skin electrical conductivity that represents sympathetic nervous system innervation of eccrine sweat glands, and hence sympathetic nervous system activity that innervates eccrine sweat glands. Objective: Our goal is to assess electrodermal activity and, as a result, sympathetic activity in diabetic rats given vildagliptin, metformin, or a combination of metformin and vildagliptin (M+V). Materials and Methods: In this investigation, 50 male rats were employed. The rats were split into ten control groups and forty experimental groups. In the experimental group, forty rats were given a single injection of 45 mg/kg streptozotocin. Three days later, blood glucose readings were taken, and it was discovered that all of the animals' blood glucose levels were above 250 mg/dl, indicating that they were diabetic. Diabetes, vildagliptin, metformin, and M+V were used to split rats into four groups. For 15 days, gavage was used to deliver vildagliptin (50 mg/kg), metformin (500 mg/kg), and M+V (50 mg/kg vildagliptin+500 mg/kg metformin). Before the sound stimulus, the response formed following the tonic and auditory stimulation was recorded as the phasic skin conductivity level (SCL) using the Biopac MP35 device, after checking blood sugars again at the conclusion of the 15 days and observing that diabetes persists. A one-way Anova test was used to assess group differences. The significance between the groups was determined using the Tukey test. The significance level was set at P0.05. Results: The M+V group had lower tonic SCL than the other experimental groups, while the metformin group had lower phasic SCL than the diabetes group (p0.0001). In the tonic recording, the peak number of vildagliptin and M+V groups was reduced compared to the diabetic group (p0.0001, p0.01). The M+V groups had lower blood sugar levels than the diabetic group. Conclusion: The fact that diabetes medicines reduced SCL in our investigation suggests that these drugs suppress eccrine sweat glands and sympathetic activity that affects these glands. More research is needed to see if lowering sympathetic activity has a good impact on diabetes.